| Symbol | HALO |
|---|---|
| Name | HALOZYME THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 11388 SORRENTO VALLEY ROAD, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 794-8889 |
| Fax | — |
| — | |
| Website | https://www.halozyme.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001159036 |
| Description | Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The companys operations are based in the United States, with minimal long-lived assets located internationally. Additional info from NASDAQ: |
2026-06-15 20:09
Snyder Mark Howard 🟡 adjusted position in 2.7K shares (1 derivative) of HALOZYME THERAPEUTICS, INC. (HALO) at $69.50 Transaction Date: Jun 12, 2026 | Filing ID: 000077
Read more
2026-06-15 10:00
Halozyme - Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Read more
2026-06-15 10:00
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
Read more
2026-06-09 17:59
New Form 3 - HALOZYME THERAPEUTICS, INC. <b>Filed:</b> 2026-06-09 <b>AccNo:</b> 0001159036-26-000076 <b>Size:</b> 643 KB
Read more
2026-06-04 00:06
Director Torley Helen 🟡 adjusted position in 50.0K shares (3 derivative) of HALOZYME THERAPEUTICS, INC. (HALO) at $69.69 ($4.6M) Transaction Date: Jun 01, 2026 | Filing ID: 000074
Read more
2026-06-02 21:20
Director Connaughton Bernadette 🔴 sold 1.6K shares of HALOZYME THERAPEUTICS, INC. (HALO) at $66.21 Transaction Date: Jun 01, 2026 | Filing ID: 000072
Read more
2026-05-15 20:13
📋 NICOLE LABROSSE (Ex-Officer) plans to sell 15K shares of HALOZYME THERAPEUTICS, INC. (at $67.12 each, total $987K) Filed: May 15, 2026 | ID: 004590
Read more
2026-05-13 21:50
Director Torley Helen 🟡 adjusted position in 50.0K shares (3 derivative) of HALOZYME THERAPEUTICS, INC. (HALO) at $73.12 ($4.6M) Transaction Date: May 11, 2026 | Filing ID: 000070
Read more
2026-05-11 20:10
📋 Helen Torley (President, CEO, Director) plans to sell 102K shares of Halozyme Therapeutics, Inc. (at $64.12 each, total $6.5M) Filed: May 11, 2026 | ID: 000422
Read more
2026-05-11 20:06
(10% Negative) HALOZYME THERAPEUTICS, INC. (HALO) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06689085 | 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOST… | Phase3 | Hypogonadism, Male | Recruiting | 2025-03-07 | 2030-03-01 | ClinicalTrials.gov |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocar… | Phase2 | Pancreatic Ductal Adenocarcinoma | Withdrawn | 2020-01-01 | 2022-11-11 | ClinicalTrials.gov |
| NCT03979066 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Aden… | Phase2 | Pancreatic Ductal Adenocarcinoma | Terminated | 2019-11-01 | 2019-11-03 | ClinicalTrials.gov |
| NCT03634332 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | Phase2 | Pancreatic Ductal Adenocarcinoma | Unknown | 2019-05-01 | 2021-01-01 | ClinicalTrials.gov |
| NCT03281369 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With… | Phase1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | Completed | 2017-10-13 | 2025-10-09 | ClinicalTrials.gov |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezo… | Phase1 | Cholangiocarcinoma Non-resectable | Terminated | 2017-10-02 | 2019-11-11 | ClinicalTrials.gov |
| NCT02921022 | Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Panc… | Na | Pancreatic Cancer | Active_Not_Recruiting | 2016-10-01 | 2026-10-01 | ClinicalTrials.gov |
| NCT02753595 | Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyal… | Phase1 | Metastatic Breast Cancer | Terminated | 2016-07-13 | 2019-08-16 | ClinicalTrials.gov |
| NCT02715804 | A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Pa… | Phase3 | Pancreatic Ductal Carcinoma | Terminated | 2016-03-14 | 2019-11-04 | ClinicalTrials.gov |
| NCT02667223 | Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combine… | Phase1 | Healthy | Terminated | 2016-02-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT02563548 | A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizum… | Phase1 | NSCLC | Completed | 2015-10-22 | 2019-03-26 | ClinicalTrials.gov |
| NCT02346370 | A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combine… | Phase1 | Non-small Cell Lung Cancer | Terminated | 2015-02-10 | 2016-11-14 | ClinicalTrials.gov |
| NCT01959139 | S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic … | Phase1 | Metastatic Pancreatic Adenocarcinoma | Completed | 2014-01-23 | 2023-11-09 | ClinicalTrials.gov |
| NCT03662334 | A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Sub… | Phase4 | Type 1 Diabetes Mellitus | Completed | 2013-10-03 | 2014-02-27 | ClinicalTrials.gov |
| NCT01839487 | PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus … | Phase2 | Metastatic Pancreatic Cancer | Completed | 2013-05-14 | 2018-09-26 | ClinicalTrials.gov |
| NCT01848990 | CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronida… | Phase4 | Type 1 Diabetes Mellitus | Completed | 2013-03-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01572012 | Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinan… | Phase1 | Healthy | Completed | 2012-02-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT01526733 | Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, P… | Phase4 | Type 1 Diabetes Mellitus | Completed | 2011-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01426763 | A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration … | Phase2 | Hereditary Angioedema | Completed | 2011-09-12 | 2011-11-28 | ClinicalTrials.gov |
| NCT01453153 | Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untr… | Phase1 | Stage IV Pancreatic Cancer | Completed | 2011-09-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT01275131 | Randomized, Double-blind, Crossover, Pharmacokinetic (PK) and Glucodynamic (GD)… | Phase1 | Type 1 Diabetes Mellitus | Completed | 2011-01-01 | 2011-12-01 | ClinicalTrials.gov |
| NCT01194245 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to … | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2010-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01194258 | Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to … | Phase2 | Diabetes Mellitus, Type II | Completed | 2010-08-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT01170897 | Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously t… | Phase1 | Solid Tumor | Completed | 2010-07-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01116102 | Study of In-line Pressure Using Various Techniques of Subcutaneous Administrati… | Phase4 | Dehydration | Terminated | 2010-05-01 | 2010-06-01 | ClinicalTrials.gov |
| NCT01120431 | Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus O… | Phase4 | Dehydration | Withdrawn | 2010-05-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00979875 | A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin… | Phase1 | Healthy | Completed | 2009-09-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00916357 | Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronid… | Phase2 | Diabetes Mellitus, Type 2 | Completed | 2009-07-01 | 2009-11-01 | ClinicalTrials.gov |
| NCT00928447 | Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With N… | Phase2 | Dermatitis, Allergic Contact | Completed | 2009-06-23 | 2009-09-13 | ClinicalTrials.gov |
| NCT00883558 | Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to In… | Phase2 | Diabetes Mellitus, Type 1 | Completed | 2009-05-01 | 2010-04-01 | ClinicalTrials.gov |
| NCT00862849 | Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Adminis… | Phase1 | Diabetes Mellitus | Completed | 2009-03-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00834704 | Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors | Phase1 | Solid Tumor | Completed | 2009-02-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT00807963 | Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonat… | Phase1 | Risk Factors for or a Diagnosis of Osteoporosis | Completed | 2008-12-01 | 2009-09-21 | ClinicalTrials.gov |
| NCT00807885 | Study of Techniques of Subcutaneous Administration of Fluids Enabled by Human R… | Phase4 | Dehydration | Completed | 2008-12-01 | 2009-01-01 | ClinicalTrials.gov |
| NCT00803972 | Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability … | Phase1 | Healthy Volunteers | Completed | 2008-11-01 | 2009-08-28 | ClinicalTrials.gov |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in P… | Phase1 | Superficial Bladder Cancer | Completed | 2008-10-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00773175 | Subcutaneous Rehydration Compared to Intravenous Rehydration | Phase4 | Dehydration | Completed | 2008-10-01 | 2009-12-01 | ClinicalTrials.gov |
| NCT00774800 | Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH… | Phase2 | Type 1 Diabetes Mellitus | Completed | 2008-10-01 | 2009-03-01 | ClinicalTrials.gov |
| NCT00705536 | Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously … | Phase1 | Diabetes Mellitus | Completed | 2007-12-01 | 2008-02-01 | ClinicalTrials.gov |
| NCT00656370 | Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hyl… | Phase4 | Healthy | Completed | 2007-12-01 | 2008-01-30 | ClinicalTrials.gov |
| NCT00477152 | Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infa… | Phase4 | Dehydration | Completed | 2007-08-01 | 2008-06-01 | ClinicalTrials.gov |
| NCT00493220 | Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous … | Phase1 | Healthy | Completed | 2007-06-01 | 2007-09-01 | ClinicalTrials.gov |
| NCT00435604 | A Study of the Subcutaneous Injection of a Viscous Antibody Solution With Recom… | Phase1 | Healthy | Completed | 2007-02-01 | 2007-05-01 | ClinicalTrials.gov |
| NCT00369187 | Study of a Large Protein Molecule Administered With Escalating Doses of Recombi… | Phase4 | Rheumatoid Arthritis | Completed | 2006-07-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00318643 | Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination Wit… | Phase1 | Bladder Cancer | Completed | 2006-03-30 | 2009-08-11 | ClinicalTrials.gov |
| NCT00593281 | INFUSE Morphine Study | Phase3 | Pain | Completed | 2006-01-01 | 2006-10-01 | ClinicalTrials.gov |
| NCT00311519 | A Phase IIIB Dose Comparison Study of Subcutaneous Hydration With and Without H… | Phase4 | Healthy | Completed | 2005-11-01 | 2006-01-01 | ClinicalTrials.gov |
Total clinical trials: 47
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Atezolizumab | Other | Phase PHASE1 | Cholangiocarcinoma Non-resectable | TERMINATED | NCT03267940 |
| GEM | Other | Phase PHASE1 | Cholangiocarcinoma Non-resectable | TERMINATED | NCT03267940 |
| CIS | Other | Phase PHASE1 | Cholangiocarcinoma Non-resectable | TERMINATED | NCT03267940 |
| PEGPH20 | Other | Phase PHASE1 | Cholangiocarcinoma Non-resectable | TERMINATED | NCT03267940 |
| Gemcitabine | Other | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| nab-Paclitaxel | Other | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| Placebo | Other | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20) | Other | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution | Other | Phase PHASE4 | Dehydration | TERMINATED | NCT01116102 |
| Ondansetron solution | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Zofran ODT | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Ondansetron + Hylenex | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Ondansetron | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| PEGPH20 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT01170897 |
| Insulin aspart | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00979875 |
| Insulin glulisine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00979875 |
| Insulin lispro | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00979875 |
| Recombinant human hyaluronidase PH20 (rHuPH20) | Other | Phase PHASE1 | Healthy | COMPLETED | NCT00979875 |
| Recombinant human hyaluronidase PH20 (rHuPH20) | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01275131 |
| Insulin aspart | Other | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01275131 |
| Insulin glargine | Other | Phase PHASE2 | Diabetes Mellitus, Type II | COMPLETED | NCT01194258 |
| Insulin glulisine | Other | Phase PHASE2 | Diabetes Mellitus, Type II | COMPLETED | NCT01194258 |
| Recombinant human hyaluronidase PH20 | Other | Phase PHASE2 | Diabetes Mellitus, Type II | COMPLETED | NCT01194258 |
| Insulin aspart | Other | Phase PHASE2 | Diabetes Mellitus, Type II | COMPLETED | NCT01194258 |
| Insulin lispro | Other | Phase PHASE2 | Diabetes Mellitus, Type II | COMPLETED | NCT01194258 |
| Cohort 4: bococizumab 300 mg + rHuPH20 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 5: bococizumab 450 mg + rHuPH20 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 3: bococizumab 300 mg + rHuPH20 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 2: bococizumab 300 mg | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 1: bococizumab 150 mg + rHuPH20 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Isotonic hydration fluid and recombinant human hyaluronidase | Other | Phase PHASE4 | Dehydration | WITHDRAWN | NCT01120431 |
| Oral rehydration fluid | Other | Phase PHASE4 | Dehydration | WITHDRAWN | NCT01120431 |
| Insulin glulisine | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Insulin aspart | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Insulin lispro | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Precommercial Hylenex recombinant (hyaluronidase human injection) | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Commercial Hylenex® recombinant (hyaluronidase human injection) | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Placebo | Other | Phase PHASE1 | Stage IV Pancreatic Cancer | COMPLETED | NCT01453153 |
| PEGPH20 | Other | Phase PHASE1 | Stage IV Pancreatic Cancer | COMPLETED | NCT01453153 |
| Gemcitabine | Other | Phase PHASE1 | Stage IV Pancreatic Cancer | COMPLETED | NCT01453153 |
| Sham injection | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT03662334 |
| Rapid Acting insulin with pre-treatment of rHuPH20 | Drug | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT03662334 |
| Docetaxel | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02346370 |
| PEGylated recombinant human hyaluronidase PH20 | Other | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02346370 |
| Insulin lispro | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01526733 |
| Insulin aspart | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01526733 |
| Recombinant human hyaluronidase PH20 | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01526733 |
| Sham Injection | Other | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01526733 |
| Insulin glargine | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT01194245 |
| Insulin glulisine | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT01194245 |
| Insulin aspart | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT01194245 |
| recombinant human hyaluronidase PH20 | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT01194245 |
| Insulin lispro | Other | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT01194245 |
| Pembrolizumab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | UNKNOWN | NCT03634332 |
| PEGPH20 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | UNKNOWN | NCT03634332 |
| Gemcitabine | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | WITHDRAWN | NCT04134468 |
| Abraxane | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | WITHDRAWN | NCT04134468 |
| Pegvorhyaluronidase alfa | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | WITHDRAWN | NCT04134468 |
| Pembrolizumab | Other | Phase PHASE1 | NSCLC | COMPLETED | NCT02563548 |
| PEGPH20 | Other | Phase PHASE1 | NSCLC | COMPLETED | NCT02563548 |
| Biologic: PEGylated recombinant human hyaluronidase | Other | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02753595 |
| Biologic: PEGylated recombinant human hyaluronidase (PEGPH20) | Other | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02753595 |
| Eribulin mesylate | Other | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02753595 |
| Enoxaparin | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| Dexamethasone | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| Gemcitabine | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| Nab-paclitaxel | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| PEGPH20 | Other | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| PEGPH20 | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT03979066 |
| Atezolizumab | Other | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT03979066 |
| CINRYZE with rHuPH20 | Other | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT01426763 |
| 5-fluorouracil | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| Irinotecan | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| Leucovorin | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| Oxaliplatin | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| PEGPH20 | Other | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| PEGPH20 | Other | Approved | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT02921022 |
| Nab-paclitaxel | Other | Approved | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT02921022 |
| Gemcitabine | Other | Approved | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT02921022 |
| Tiragolumab | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Cisplatin | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Linagliptin | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| BL-8040 | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| PEGylated recombinant human hyaluronidase (PEGPH20) | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Paclitaxel | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Ramucirumab | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Cobimetinib | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Atezolizumab | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Oxaliplatin | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Leucovorin | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| 5-Fluorouracil (5-FU) | Other | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Testosterone enanthate | Other | Phase PHASE3 | Hypogonadism, Male | RECRUITING | NCT06689085 |
| Abraxane | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | WITHDRAWN | NCT04134468 |
| Pegvorhyaluronidase alfa | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | WITHDRAWN | NCT04134468 |
| Sham injection | DEVICE | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT03662334 |
| Rapid Acting insulin with pre-treatment of rHuPH20 | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT03662334 |
| Tiragolumab | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Cisplatin | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Linagliptin | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| BL-8040 | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| PEGylated recombinant human hyaluronidase (PEGPH20) | BIOLOGICAL | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Paclitaxel | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Ramucirumab | BIOLOGICAL | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Cobimetinib | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| 5-Fluorouracil (5-FU) | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Atezolizumab | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT03979066 |
| GEM | DRUG | Phase PHASE1 | Cholangiocarcinoma Non-resectable | TERMINATED | NCT03267940 |
| CIS | DRUG | Phase PHASE1 | Cholangiocarcinoma Non-resectable | TERMINATED | NCT03267940 |
| Biologic: PEGylated recombinant human hyaluronidase | OTHER | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02753595 |
| Biologic: PEGylated recombinant human hyaluronidase (PEGPH20) | OTHER | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02753595 |
| Eribulin mesylate | DRUG | Phase PHASE1 | Metastatic Breast Cancer | TERMINATED | NCT02753595 |
| nab-Paclitaxel | DRUG | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20) | OTHER | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| Cohort 4: bococizumab 300 mg + rHuPH20 | BIOLOGICAL | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 5: bococizumab 450 mg + rHuPH20 | BIOLOGICAL | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 3: bococizumab 300 mg + rHuPH20 | BIOLOGICAL | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 2: bococizumab 300 mg | BIOLOGICAL | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Cohort 1: bococizumab 150 mg + rHuPH20 | BIOLOGICAL | Phase PHASE1 | Healthy | TERMINATED | NCT02667223 |
| Pembrolizumab | BIOLOGICAL | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | UNKNOWN | NCT03634332 |
| Docetaxel | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02346370 |
| PEGylated recombinant human hyaluronidase PH20 | DRUG | Phase PHASE1 | Non-small Cell Lung Cancer | TERMINATED | NCT02346370 |
| 5-fluorouracil | DRUG | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| Irinotecan | DRUG | Phase PHASE1 | Metastatic Pancreatic Adenocarcinoma | COMPLETED | NCT01959139 |
| Leucovorin | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Oxaliplatin | DRUG | Phase PHASE1 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | COMPLETED | NCT03281369 |
| Precommercial Hylenex recombinant (hyaluronidase human injection) | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Commercial Hylenex® recombinant (hyaluronidase human injection) | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Enoxaparin | DRUG | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| Dexamethasone | DRUG | Phase PHASE2 | Metastatic Pancreatic Cancer | COMPLETED | NCT01839487 |
| Nab-paclitaxel | DRUG | Approved | Pancreatic Cancer | ACTIVE_NOT_RECRUITING | NCT02921022 |
| Ondansetron solution | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Zofran ODT | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Ondansetron + Hylenex | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Ondansetron | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01572012 |
| Sham Injection | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01526733 |
| Gemcitabine | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | WITHDRAWN | NCT04134468 |
| CINRYZE with rHuPH20 | BIOLOGICAL | Phase PHASE2 | Hereditary Angioedema | COMPLETED | NCT01426763 |
| Recombinant human hyaluronidase PH20 | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01526733 |
| Isotonic hydration fluid and recombinant human hyaluronidase | DRUG | Phase PHASE4 | Dehydration | WITHDRAWN | NCT01120431 |
| Oral rehydration fluid | OTHER | Phase PHASE4 | Dehydration | WITHDRAWN | NCT01120431 |
| Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution | DRUG | Phase PHASE4 | Dehydration | TERMINATED | NCT01116102 |
| Insulin aspart | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Insulin glulisine | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Insulin lispro | DRUG | Phase PHASE4 | Type 1 Diabetes Mellitus | COMPLETED | NCT01848990 |
| Placebo | DRUG | Phase PHASE3 | Pancreatic Ductal Carcinoma | TERMINATED | NCT02715804 |
| Insulin glargine | DRUG | Phase PHASE2 | Diabetes Mellitus, Type II | COMPLETED | NCT01194258 |
| recombinant human hyaluronidase PH20 | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT01194245 |
| regular human insulin | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00883558 |
| Regular Human Insulin | DRUG | Phase PHASE1 | Diabetes Mellitus | COMPLETED | NCT00862849 |
| Insulin Lispro | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 1 | COMPLETED | NCT00883558 |
| PEGPH20 | DRUG | Phase PHASE2 | Pancreatic Ductal Adenocarcinoma | TERMINATED | NCT03979066 |
| zoledronic acid | DRUG | Phase PHASE1 | Risk Factors for or a Diagnosis of Osteoporosis | COMPLETED | NCT00807963 |
| hylenex-facilitated subcutaneous Lactated Ringer's infusion | DRUG | Phase PHASE4 | Dehydration | COMPLETED | NCT00807885 |
| Insulin Lispro Injection | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00803972 |
| Insulin Human Injection | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT00803972 |
| rHuPH20 | DRUG | Phase PHASE2 | Dermatitis, Allergic Contact | COMPLETED | NCT00928447 |
| Liquid meal | OTHER | Phase PHASE2 | Type 1 Diabetes Mellitus | COMPLETED | NCT00774800 |
| Recombinant human hyaluronidase PH20 (rHuPH20) | DRUG | Phase PHASE1 | Type 1 Diabetes Mellitus | COMPLETED | NCT01275131 |
| Humulin-R | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00916357 |
| Humalog | DRUG | Phase PHASE2 | Diabetes Mellitus, Type 2 | COMPLETED | NCT00916357 |
| large protein molecule | DRUG | Phase PHASE4 | Rheumatoid Arthritis | COMPLETED | NCT00369187 |
| recombinant human hyaluronidase | DRUG | Phase PHASE4 | Dehydration | COMPLETED | NCT00773175 |
| IV Ceftriaxone | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00493220 |
| SC Placebo and Ceftriaxone | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00493220 |
| SC HYLENEX and Ceftriaxone | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT00493220 |
| hyaluronidase (human recombinant)/rehydration fluid | DRUG | Phase PHASE4 | Dehydration | COMPLETED | NCT00477152 |
| Chemophase | DRUG | Phase PHASE1 | Superficial Bladder Cancer | COMPLETED | NCT00782587 |
| Mitomycin C | DRUG | Phase PHASE1 | Bladder Cancer | COMPLETED | NCT00318643 |
| Hylenex | DRUG | Phase PHASE3 | Pain | COMPLETED | NCT00593281 |
Total products: 169